Tapper Elliot B, Jiang Z Gordon, Patwardhan Vilas R
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA.
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA.
Mayo Clin Proc. 2015 May;90(5):646-58. doi: 10.1016/j.mayocp.2015.03.003. Epub 2015 Apr 9.
Hepatic encephalopathy (HE) is one of the most important complications of cirrhosis and portal hypertension. Although the etiology is incompletely understood, it has been linked to ammonia directly and indirectly. Our goal is to review for the clinician the mechanisms behind hyperammonemia and the pathogenesis of HE to explain the rationale for its therapy. We reviewed articles collected through a search of MEDLINE/PubMed, Cochrane Database of Systematic Reviews, and Google Scholar between October 1, 1948, and December 8, 2014, and by a manual search of citations within retrieved articles. Search terms included hepatic encephalopathy, ammonia hypothesis, brain and ammonia, liver failure and ammonia, acute-on-chronic liver failure and ammonia, cirrhosis and ammonia, portosytemic shunt, ammonia and lactulose, rifaximin, zinc, and nutrition. Ammonia homeostatsis is a multiorgan process involving the liver, brain, kidneys, and muscle as well as the gastrointestinal tract. Indeed, hyperammonemia may be the first clue to poor functional reserves, malnutrition, and impending multiorgan dysfunction. Furthermore, the neuropathology of ammonia is critically linked to states of systemic inflammation and endotoxemia. Given the complex interplay among ammonia, inflammation, and other factors, ammonia levels have questionable utility in the staging of HE. The use of nonabsorbable disaccharides, antibiotics, and probiotics reduces gut ammoniagenesis and, in the case of antibiotics and probiotics, systemic inflammation. Nutritional support preserves urea cycle function and prevents wasting of skeletal muscle, a significant site of ammonia metabolism. Correction of hypokalemia, hypovolemia, and acidosis further assists in the reduction of ammonia production in the kidney. Finally, early and aggressive treatment of infection, avoidance of sedatives, and modification of portosystemic shunts are also helpful in reducing the neurocognitive effects of hyperammonemia. Refining the ammonia hypothesis to account for these other factors instructs a solid foundation for the effective treatment and prevention of hepatic encephalopathy.
肝性脑病(HE)是肝硬化和门静脉高压最重要的并发症之一。尽管其病因尚未完全明确,但已发现它与氨存在直接和间接关联。我们的目标是为临床医生回顾高氨血症背后的机制以及肝性脑病的发病机制,以解释其治疗原理。我们检索了1948年10月1日至2014年12月8日期间MEDLINE/PubMed、Cochrane系统评价数据库和谷歌学术收录的文章,并通过手动检索所获文章中的参考文献。检索词包括肝性脑病、氨假说、脑与氨、肝衰竭与氨、慢加急性肝衰竭与氨、肝硬化与氨、门体分流、氨与乳果糖、利福昔明、锌和营养。氨稳态是一个涉及肝脏、脑、肾脏、肌肉以及胃肠道的多器官过程。事实上,高氨血症可能是功能储备不佳、营养不良和即将发生多器官功能障碍的首要线索。此外,氨的神经病理学与全身炎症和内毒素血症状态密切相关。鉴于氨、炎症和其他因素之间复杂的相互作用,氨水平在肝性脑病分期中的作用存疑。使用不可吸收双糖、抗生素和益生菌可减少肠道氨生成,而抗生素和益生菌还可减轻全身炎症。营养支持可维持尿素循环功能,防止骨骼肌消耗,骨骼肌是氨代谢的重要场所。纠正低钾血症、低血容量和酸中毒有助于进一步减少肾脏氨生成。最后,早期积极治疗感染、避免使用镇静剂以及改良门体分流也有助于减轻高氨血症的神经认知影响。完善氨假说以考虑这些其他因素为有效治疗和预防肝性脑病奠定了坚实基础。